Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biohaven Pharmaceutical Holding Co Ltd.

20.71
-2.9700-12.54%
Volume:1.71M
Turnover:36.27M
Market Cap:2.11B
PE:-2.23
High:22.24
Open:22.15
Low:20.47
Close:23.68
Loading ...

Biohaven's Q4 Non-GAAP Net Loss Widens

MT Newswires Live
·
03 Mar

Earnings Flash (BHVN) Biohaven Posts Q4 Total Operating Expenses $189.9M

MT Newswires Live
·
03 Mar

Biohaven reports ‘positive’ data from study of BHV-1300

TIPRANKS
·
03 Mar

Biohaven Ltd - Bhv-1300 Safe and Well Tolerated in Phase 1 Studies

THOMSON REUTERS
·
03 Mar

Biohaven Reports Positive Degrader Data Achieving > 80% SUSTAINED REDUCTIONS IN TOTAL IGG WITH POTENTIAL FIRST-IN-CLASS BHV-1300

THOMSON REUTERS
·
03 Mar

Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300

PR Newswire
·
03 Mar

Biohaven Q4 Profit From Operations USD -189.931 Million

THOMSON REUTERS
·
03 Mar

Biohaven Q4 Basic EPS USD -1.85

THOMSON REUTERS
·
03 Mar

FOCUS-Next generation weight loss drugs aim to save muscle

Reuters
·
19 Feb

Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT), Biohaven Ltd. (BHVN) and Arvinas Holding Company (ARVN)

TIPRANKS
·
12 Feb

Why Biohaven (BHVN) Stock Is Rallying Today

Insider Monkey
·
12 Feb

Biohaven Shares up 7.3% as FDA Grants Priority Review Status for Brain Disorder Drug

THOMSON REUTERS
·
11 Feb

BUZZ-Biohaven rises as FDA grants priority review status for brain disorder drug

Reuters
·
11 Feb

Sector Update: Health Care Stocks Mixed Premarket Tuesday

MT Newswires Live
·
11 Feb

Biohaven Says FDA Grants Priority Review to Neurodegenerative Disorder Drug; Shares Rise

MT Newswires Live
·
11 Feb

BRIEF-Biohaven Announces FDA Acceptance And Priority Review Of Troriluzole New Drug Application

Reuters
·
11 Feb

Biohaven Gets FDA Priority Review of Troriluzole for Spinocerebellar Ataxia

Dow Jones
·
11 Feb

Biohaven Ltd - FDA Decision on Troriluzole Nda Expected by 3Q2025

THOMSON REUTERS
·
11 Feb

Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia

THOMSON REUTERS
·
11 Feb

Biohaven Ltd - Prepared to Commercialize Troriluzole for SCA in 2025

THOMSON REUTERS
·
11 Feb